Corinna Kosnopfel

11PUBLICATIONS
25CO-AUTHORS
Gene and molecular therapyMolecular targetsPredictive and prognostic markersMedical infection agents (incl. prions)Haematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Oct 16, 2025
Combinatorial ERK Inhibition Enhances MAPK Pathway Suppression in BRAF-Mutant Melanoma.

Corinna Kosnopfel, Tobias Sinnberg, Shrunal Mane

|May 29, 2024
Loss of p14 diminishes immunogenicity in melanoma via non-canonical Wnt signaling by reducing the peptide surface density.

Jonas Wohlfarth, Corinna Kosnopfel, Dominic Faber

|May 11, 2024
Susceptibility of Melanoma Cells to Targeted Therapy Correlates with Protection by Blood Neutrophils.

Simone Wendlinger, Jonas Wohlfarth, Claudia Siedel

|Dec 09, 2023
Exploring the In Vitro and In Vivo Therapeutic Potential of BRAF and MEK Inhibitor Combination in NRAS-Mutated Melanoma.

Heike Niessner, Anna Hüsch, Corinna Kosnopfel

|Jul 18, 2023
Inhibition of p90 ribosomal S6 kinases disrupts melanoma cell growth and immune evasion.

Corinna Kosnopfel, Simone Wendlinger, Heike Niessner

|Nov 09, 2022
mTOR inhibition amplifies the anti-lymphoma effect of PI3Kβ/δ blockage in diffuse large B-cell lymphoma.

Wendan Xu, Philipp Berning, Tabea Erdmann

Pageof 2

Frequent Collaborators

5 joint publications

Bastian Schilling

4 joint publications

Tobias Sinnberg

2 joint publications

David Schrama

2 joint publications

Jonas Wohlfarth